TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quite Smoking Program for Lung Cancer Patients' Families
Brief Summary: The purpose of this study is to evaluate the impact of delivering a coping-focused intervention as an adjunct to a self-help program to promote smoking cessation among relatives of lung cancer patients.


Options:
A: Intervention Type: BEHAVIORAL; Name: Coping-focused counseling telephone calls; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Brief Advice (SBA) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Structured Brief Advice (SBA); Assigned to Arm(s): 2
C: Arm Label: Brief Advice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Advice (BA) | Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education (HE) | Intervention Type: BEHAVIORAL; Name: Brief Advice (BA); Assigned to Arm(s): Brief Advice | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Health Education (HE); Assigned to Arm(s): Health Education
D: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation advice, Behavioral: Spirometry and smoking cessation advice | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Spirometry and smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam
Brief Summary: To provide specific data on immunogenicity of GSK Biologicals' HRV liquid vaccine, when co-administered with the routine Expanded Program of Immunization (EPI) in Vietnam. The study will also assess reactogenicity and safety of the HRV liquid vaccine relative to the placebo


Options:
A: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
C: Arm Label: V260 with staggered EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with staggered EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Arm Label: V260 with concomitant EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with concomitant EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Intervention Type: BIOLOGICAL; Name: V260; Assigned to Arm(s): V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: Placebo to V260; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: DTaP; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI
D: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam
Brief Summary: To provide specific data on immunogenicity of GSK Biologicals' HRV liquid vaccine, when co-administered with the routine Expanded Program of Immunization (EPI) in Vietnam. The study will also assess reactogenicity and safety of the HRV liquid vaccine relative to the placebo


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
B: Arm Label: LBRV-PV Lot A; Type: EXPERIMENTAL; Interventions: Biological: Liquid Rotavirus Vaccine | Arm Label: LBRV-PV Lot B; Type: EXPERIMENTAL; Interventions: Biological: Liquid Rotavirus Vaccine | Arm Label: LBRV-PV Lot C; Type: EXPERIMENTAL; Interventions: Biological: Liquid Rotavirus Vaccine | Arm Label: ROTASIIL; Type: ACTIVE_COMPARATOR; Interventions: Biological: Liquid Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Liquid Rotavirus Vaccine; Assigned to Arm(s): LBRV-PV Lot A, LBRV-PV Lot B, LBRV-PV Lot C, ROTASIIL
C: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
D: Arm Label: Rotavirus Vaccine at age 6 & 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 10 & 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 6,10,&14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Human Rotavirus Vaccine; Assigned to Arm(s): Rotavirus Vaccine at age 6 & 10 weeks, Rotavirus vaccine at age 10 & 14 weeks, Rotavirus vaccine at age 6,10,&14 weeks

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam
Brief Summary: To provide specific data on immunogenicity of GSK Biologicals' HRV liquid vaccine, when co-administered with the routine Expanded Program of Immunization (EPI) in Vietnam. The study will also assess reactogenicity and safety of the HRV liquid vaccine relative to the placebo


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
B: Arm Label: Study Group 1: DAPTACEL®, ActHIB®, and IPOL®; Type: EXPERIMENTAL; Interventions: Biological: DAPTACEL®. (DTaP), IPOL®., and ActHIB®. | Arm Label: Study Group 2: Pentacel®; Type: EXPERIMENTAL; Interventions: Biological: Pentacel®: DTaP-IPV/Hib combined | Arm Label: Study Group 3: DTaP-IPV and ActHIB®; Type: EXPERIMENTAL; Interventions: Biological: DTaP-IPV and ActHIB® | Arm Label: Study Group 4: Pentacel®; Type: EXPERIMENTAL; Interventions: Biological: Pentacel®: DTaP-IPV/Hib combined | Intervention Type: BIOLOGICAL; Name: DAPTACEL®. (DTaP), IPOL®., and ActHIB®.; Assigned to Arm(s): Study Group 1: DAPTACEL®, ActHIB®, and IPOL® | Intervention Type: BIOLOGICAL; Name: Pentacel®: DTaP-IPV/Hib combined; Assigned to Arm(s): Study Group 2: Pentacel® | Intervention Type: BIOLOGICAL; Name: DTaP-IPV and ActHIB®; Assigned to Arm(s): Study Group 3: DTaP-IPV and ActHIB® | Intervention Type: BIOLOGICAL; Name: Pentacel®: DTaP-IPV/Hib combined; Assigned to Arm(s): Study Group 4: Pentacel®
C: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
D: Arm Label: Cohort A P2-VP8 30 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort A P2-VP8 60 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort B P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Arm Label: Cohort B placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort B P2-VP8 30mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort B1 P2-VP8 60mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort A P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 10mcg; Assigned to Arm(s): Cohort A P2-VP8 10mcg, Cohort B P2-VP8 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 30 mcg; Assigned to Arm(s): Cohort A P2-VP8 30 mcg, Cohort B P2-VP8 30mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 60mcg; Assigned to Arm(s): Cohort A P2-VP8 60 mcg, Cohort B1 P2-VP8 60mcg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort B placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Augmenting Clozapine With Sertindole - a Double Blinded Randomized Placebo Study
Brief Summary: The purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Serdolect | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Serdolect; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: pimozide; Type: EXPERIMENTAL; Interventions: Drug: Pimozide | Intervention Type: DRUG; Name: Pimozide; Assigned to Arm(s): pimozide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Week, Open-Label, Safety Trial Of Pregabalin In Patients With Fibromyalgia
Brief Summary: The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081100 and who wish to receive open-label pregabalin therapy.


Options:
A: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
C: Arm Label: Flexible Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Fixed Dosing; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Fixed Dosing, Flexible Dose
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen
Brief Summary: To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain. For this purpose, patients with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease will be recruited. The cardiovascular, gastrointestinal and renal safety and symptomatic benefit in each treatment group will be assessed accordingly.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B
B: Arm Label: celecoxib; Type: EXPERIMENTAL; Interventions: Drug: celecoxib | Arm Label: ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: naproxen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naproxen | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): celecoxib | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): ibuprofen | Intervention Type: DRUG; Name: Naproxen; Assigned to Arm(s): naproxen
C: Intervention Type: DRUG; Name: celecoxib, esomeprazole; Assigned to Arm(s): N/A
D: Arm Label: Pelubiprofen 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Pelubiprofen 30 mg | Arm Label: Celebrex 200 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Celebrex 200 mg | Intervention Type: DRUG; Name: Pelubiprofen 30 mg; Assigned to Arm(s): Pelubiprofen 30 mg | Intervention Type: DRUG; Name: Celebrex 200 mg; Assigned to Arm(s): Celebrex 200 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events
Brief Summary: The evaluation of efficacy is performed by laboratory monitoring of bone density and resorption markers and clinical monitoring of bone density improvement. This is a prospective, randomized, parallel group, single blind study of one year treatment with zoledronic acid every 6 months as compared to one year treatment with zoledronic acid every 3 months and to placebo every 3 months in patients with hemoglobin syndromes and risk of skeletal complications.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M
B: Arm Label: Denosumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
D: Arm Label: Placebo Capsule; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Zinc (25 mg/d); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Zinc (25 mg/d) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo Capsule

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease (ITN025AD)
Brief Summary: The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Staloral | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Staloral | Intervention Type: DRUG; Name: Staloral; Assigned to Arm(s): 1, 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Birch pollen allergen extract; Type: EXPERIMENTAL; Interventions: Biological: Birch pollen allergen extract | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Birch pollen allergen extract; Assigned to Arm(s): Birch pollen allergen extract
C: Arm Label: Oral mucosal immunoprophylaxis (OMIP); Type: EXPERIMENTAL; Interventions: Biological: Oral mucosal immunoprophylaxis (OMIP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Oral mucosal immunoprophylaxis (OMIP); Assigned to Arm(s): Oral mucosal immunoprophylaxis (OMIP) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: (agent for immunotherapy) Staloral | Intervention Type: DRUG; Name: (agent for immunotherapy) Staloral; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease (ITN025AD)
Brief Summary: The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the disease.


Options:
A: Arm Label: Oral mucosal immunoprophylaxis (OMIP); Type: EXPERIMENTAL; Interventions: Biological: Oral mucosal immunoprophylaxis (OMIP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Oral mucosal immunoprophylaxis (OMIP); Assigned to Arm(s): Oral mucosal immunoprophylaxis (OMIP) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Short ragweed pollen allergen extract; Type: EXPERIMENTAL; Interventions: Biological: Short ragweed pollen allergen extract, Drug: Self-injectable epinephrine, Drug: Albuterol/Salbutamol, Drug: Loratadine, Drug: Olopatadine, Drug: Mometasone furoate monohydrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Self-injectable epinephrine, Drug: Albuterol/Salbutamol, Drug: Loratadine, Drug: Olopatadine, Drug: Mometasone furoate monohydrate | Intervention Type: BIOLOGICAL; Name: Short ragweed pollen allergen extract; Assigned to Arm(s): Short ragweed pollen allergen extract | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Self-injectable epinephrine; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Albuterol/Salbutamol; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Loratadine; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Olopatadine; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Mometasone furoate monohydrate; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Staloral | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Staloral | Intervention Type: DRUG; Name: Staloral; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa
Brief Summary: "The primary objective of this study was to demonstrate that co-administering HRV vaccine with OPV does not induce a significant decrease in poliovirus immune response one month after the third dose of combined vaccines.

The primary objective was reached if one month after the third dose of polio vaccine, upper limit of the 95% CI for the difference in Seroprotection rate between the group B and C pooled and (minus) the group A was below 10% for each polio serotype."


Options:
A: Arm Label: Cohort A P2-VP8 30 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort A P2-VP8 60 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort B P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Arm Label: Cohort B placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort B P2-VP8 30mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort B1 P2-VP8 60mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort A P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 10mcg; Assigned to Arm(s): Cohort A P2-VP8 10mcg, Cohort B P2-VP8 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 30 mcg; Assigned to Arm(s): Cohort A P2-VP8 30 mcg, Cohort B P2-VP8 30mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 60mcg; Assigned to Arm(s): Cohort A P2-VP8 60 mcg, Cohort B1 P2-VP8 60mcg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort B placebo
B: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix TM | Intervention Type: BIOLOGICAL; Name: Rotarix TM; Assigned to Arm(s): Rotarix Group

Answer: B